Results 121 to 130 of about 89,027 (290)
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen +12 more
wiley +1 more source
Deep-insights: Nanoengineered gel-based localized drug delivery for arthritis management
Arthritis is an inflammatory joint disorder that progressively impairs function and diminishes quality of life. Conventional therapies often prove ineffective, as oral administration lacks specificity, resulting in off-target side effects like ...
Anitha Sriram +2 more
doaj +1 more source
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong +9 more
wiley +1 more source
Light-Responsive and Dual-Targeting Liposomes: From Mechanisms to Targeting Strategies
In recent years, nanocarriers have played an ever-increasing role in clinical and biomedical applications owing to their unique physicochemical properties and surface functionalities. Lately, much effort has been directed towards the development of smart,
Ahmed M. Agiba +3 more
doaj +1 more source
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang +10 more
wiley +1 more source
Advances in the use of nanocarriers for cancer diagnosis and treatment
The use of nanocarriers as drug delivery systems for therapeutic or imaging agents can improve the pharmacological properties of commonly used compounds in cancer diagnosis and treatment.
Débora Braga Vieira +1 more
doaj +1 more source
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
This system adopts a biomimetic phospholipid structure, covalently binding iNOS inhibitors, neuroprotective agent PCA and vitamin E derivatives through pH/ROS dual‐responsive bonds, and assembles them with Prussian blue nanozyme to form PBB@AHA. It can efficiently penetrate the blood‐brain barrier and simultaneously release multiple active components ...
Mengcheng Guo +9 more
wiley +1 more source
Antony V Samrot,1 Teeshalini Kudaiyappan,1 Ummu Bisyarah,1 Anita Mirarmandi,1 Etel Faradjeva,1 Amira Abubakar,1 Jenifer A Selvarani,2 Suresh Kumar Subbiah3,4 1Department of Biomedical Sciences, Faculty of Medicine and Biomedical Sciences, MAHSA ...
Samrot AV +7 more
doaj
In the present study, we have demonstrated that the NUP85‐USP47‐ASK1 signaling pathway may have regulated the progression of liver fibrosis through modulating ERS. Additionally, we have developed a CREKA‐coupled liposome to target delivery of MV, a pharmacological inhibitor of NUP85, to activated HSCs, thereby attenuating liver fibrosis. ABSTRACT Liver
Dashuai Yang +11 more
wiley +1 more source

